<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="135999">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679080</url>
  </required_header>
  <id_info>
    <org_study_id>TreatOI</org_study_id>
    <nct_id>NCT01679080</nct_id>
  </id_info>
  <brief_title>The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta</brief_title>
  <official_title>The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are
      fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o. The aim of the
      present study is to investigate the effect of treatment of adult OI patients with
      bisphosphonate (zoledronic acid), parathyroid hormone (PTH) or placebo on bone mass,
      fracture risk and quality of life.

      The investigators will therefore conduct a double blind, placebo controlled trial, taking
      genotype and previous antiresorptive therapy into account.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>Three years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Dual-energy X-ray absorptiometry scans are performed at the lumbar spine, hip and whole body twice yearly. The value of the lumbar BMD is the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fracture risk</measure>
    <time_frame>Three years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants are asked to report fractures throughout the study. Medical examination yearly with a focus on possible new fractures. Columnar x-ray before and after the study investigate new fractures.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Zolendronic acid + placebo teriparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>yearly intravenous infusion of 5mg and daily injection of one dose teriparatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teriparatide + placebo zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>yearly infusion of placebo zoledronic acid (isotonic sodium chloride)and daily injection of one dose active teriparatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pcb zoledronic acid + pcb teriparatide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>yearly infusion of placebo zoledronic acid and daily injection of placebo teriparatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>antiresorptive</description>
    <arm_group_label>Zolendronic acid + placebo teriparatide</arm_group_label>
    <other_name>zolendronate</other_name>
    <other_name>Aclasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>anabolic</description>
    <arm_group_label>teriparatide + placebo zoledronic acid</arm_group_label>
    <other_name>PTH</other_name>
    <other_name>Forsteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo zoledronic acid</intervention_name>
    <arm_group_label>teriparatide + placebo zoledronic acid</arm_group_label>
    <arm_group_label>pcb zoledronic acid + pcb teriparatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo teriparatide</intervention_name>
    <arm_group_label>Zolendronic acid + placebo teriparatide</arm_group_label>
    <arm_group_label>pcb zoledronic acid + pcb teriparatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of osteogenesis imperfecta

          -  BMD&lt;-2.0 or

          -  BMD&lt;-1 and significant fracture within 3 years

          -  women postmenopausal or using accepted contraception

        Exclusion Criteria:

          -  creatinine clearance &lt;30mL/min

          -  treatment with glucocorticoids &gt; 5mg daily during the last 3 months

          -  metabolic bone disease or vitamin d deficiency

          -  liver or kidney disease

          -  contradictions to zoledronic acid or teriparatide

          -  increased baseline risk of osteosarcoma
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente Langdahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bente Langdahl</last_name>
    <phone>0045 7846 7678</phone>
    <email>bente.langdahl@aarhus.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jannie Hald</last_name>
    <phone>0045 7846 7681</phone>
    <email>janniehald@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Osteoporosis clinic; department of endocrinology and metabolism</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus C</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jannie Hald</last_name>
      <phone>0045 7846 7686</phone>
      <email>janniehald@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jannie Hald</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of endocrinology</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens-Erik B Jensen</last_name>
      <email>Jens-Erik.Beck.Jensen@hvh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jens-Erik B Jensen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology M</name>
      <address>
        <city>Odense</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Folkestad</last_name>
      <email>lfolkestad@health.sdu.dk</email>
    </contact>
    <investigator>
      <last_name>Lars Folkestad</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>August 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <keyword>Adult</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
